News

David Cameron Urges NHS to Unlock Alzheimer’s Drugs and Cap Diagnosis Waits at 18 Weeks

Former prime minister Lord David Cameron is leading a call for the NHS to fund two breakthrough Alzheimer’s drugs and to cap dementia diagnosis waits at 18 weeks, in a campaign that has put the cost of new treatments at the centre of a national debate. Cameron, who lost his mother Mary to Alzheimer’s in February 2025, has joined 48 dementia specialists, researchers and former health ministers in demanding that the medicines be made available through the health service. The drugs, lecanemab and donanemab, were licensed in Britain in 2024, yet neither is routinely available on the NHS in England and Wales outside clinical trials.

The campaign, first reported by the Telegraph on 9 November 2026, argues that families should not be forced into private care to slow a disease that affects nearly one million people in the UK. Cameron, president of Alzheimer’s Research UK, has appealed to Prime Minister Andy Burnham, saying now is the perfect time for government action, with a number of promising treatments on the horizon. The decision, however, rests with the National Institute for Health and Care Excellence, known as NICE, which is still evaluating both drugs.

David Cameron Alzheimer’s Drugs Campaign — Quick Reference Summary

DetailInformation
WhoLord David Cameron, former prime minister (2010–2016), president of Alzheimer’s Research UK
WhatCalls for NHS access to Alzheimer’s drugs lecanemab and donanemab, plus a maximum 18-week wait for dementia diagnosis
WhenCampaign reported 9 November 2026; follow-up appeal 14 November 2026; still trending in the UK on 19 November 2026
WhereUnited Kingdom — NHS in England and Wales
DrugsLecanemab (Eisai) and donanemab (Eli Lilly), licensed by the MHRA in 2024 for early Alzheimer’s
Drug costAbout £20,000 to £26,000 per patient per year, before infusion, scan and monitoring costs
EffectCan slow decline in early Alzheimer’s; NICE assessed lecanemab’s effect as a four-to-six-month delay in progression
ScaleNearly 1 million people in the UK live with dementia; 1.4 million expected by 2040; annual economic cost £42 billion (2024)
Decision-makerNICE — evaluations of both drugs in progress as of November 2026

Two Licensed Drugs, Zero NHS Access

Lecanemab and donanemab are the first drugs shown to slow cognitive decline in people with early Alzheimer’s disease, and both were licensed in Britain by the Medicines and Healthcare products Regulatory Agency in 2024. They are not cures, and they cannot restore lost memories, but they can buy patients months of slower decline. Despite that, neither drug is routinely available on the NHS in England and Wales, and eligible patients who want treatment must either join a clinical trial or pay privately.

NICE initially issued draft recommendations against both drugs in 2025, concluding that their benefits did not justify the additional cost to the NHS. The manufacturers, Eisai and Eli Lilly, appealed successfully in March 2026, and the institute agreed to reconsider both treatments. Both evaluations remained in progress as of November 2026, with no date given for a decision.

The Price Tag Blocking the Door

The medicines alone are estimated to cost about £20,000 to £26,000 per patient each year, before the additional costs of infusions, scans and monitoring. That figure sits at the heart of NICE’s hesitation, and it is also the reason Cameron’s group is calling for a dedicated dementia drugs fund. The campaign argues that the price should be negotiated down rather than used as a reason to block access altogether.

The wider economics are stark. According to the Alzheimer’s Society, nearly one million people in the UK are living with dementia, a figure expected to reach 1.4 million by 2040, and the estimated annual economic cost was already £42 billion in 2024. Against that scale, the campaigners argue, the cost of the drugs is a fraction of what dementia already costs families and the state.

The 18-Week Diagnosis Clock

Cameron’s group is also calling for a maximum 18-week wait for a dementia diagnosis, because the new drugs only work in the early stages of the disease. Research published by the Alzheimer’s Society in 2026 found that 45 per cent of surveyed carers reported waiting more than six months for a diagnosis after first seeking help. By the time many patients are diagnosed, the window in which the drugs can help has already closed.

There is currently no equivalent national dementia diagnosis target to the standards covering routine consultant-led NHS treatment or suspected cancer. The government’s forthcoming dementia and frailty framework, expected by the end of the year, offers an opportunity to introduce one. Cameron has also backed cheaper medicines whose side-effect risks are already well understood, alongside the two new drugs.

A Personal Fight for the Former Prime Minister

Cameron’s involvement is personal as well as political. His mother, Mary, died of Alzheimer’s in February 2025, and he has spoken about the disease as one that destroys lives and families. As prime minister he launched the National Dementia Challenge, doubling investment into research for dementia treatments, and he returned as president of Alzheimer’s Research UK in 2025 after previously holding the role from 2017 to 2023.

He has also expressed regret that his government did not introduce a cap on care costs, a reform that remains unfinished. In a visit to Oxford’s Centre for Medicines Discovery in November 2026, he saw first hand the progress being made in dementia research, and he has pointed to the Ad-Smart trial, backed by the prime minister last month, which experts say could more than halve the time it takes to test Alzheimer’s treatments.

What Happens Next

The decision now sits with NICE, which evaluates treatments independently on the basis of costs and benefits. A Department of Health and Social Care spokesman has confirmed that both treatments are being evaluated, and pointed to £33 million invested through the Dame Barbara Windsor Dementia Goals programme to recruit more people into clinical studies and speed up trials. No decision date has been given.

For patients, the wait continues. Those who can afford private treatment have another option, while those who cannot must wait for NICE to rule. Whether the framework expected by the end of the year brings a diagnosis target, a drugs fund, or both, will decide whether Cameron’s campaign turns into NHS policy or remains a call for action.

Frequently Asked Questions

What is David Cameron asking the NHS to do about Alzheimer’s drugs? — A: David Cameron is calling for the NHS to fund the Alzheimer’s drugs lecanemab and donanemab, which are licensed in the UK but not routinely available on the NHS, and for a maximum 18-week wait for a dementia diagnosis.

What are lecanemab and donanemab? — A: Lecanemab and donanemab are drugs for early Alzheimer’s disease that have been shown to slow cognitive decline. They were licensed in Britain in 2024. They are not cures and cannot restore lost memories.

Why are the drugs not available on the NHS? — A: NICE issued draft recommendations against both drugs in 2025, concluding their benefits did not justify the cost. After successful appeals by the manufacturers in March 2026, NICE agreed to reconsider, and both evaluations are still in progress.

How much do the Alzheimer’s drugs cost? — A: The medicines alone are estimated to cost about £20,000 to £26,000 per patient per year, before the costs of infusions, scans and monitoring.

How many people in the UK live with dementia? — A: According to the Alzheimer’s Society, nearly one million people in the UK are living with dementia, a figure expected to reach 1.4 million by 2040. The annual economic cost was estimated at £42 billion in 2024.

Who decides whether the NHS funds the drugs? — A: The National Institute for Health and Care Excellence, NICE, decides independently whether treatments are approved for routine NHS use, based on an evidence-based assessment of costs and benefits.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button

Adblock Detected

It looks like you are using an Ad Blocker. To view the full content on this website, please turn off your Ad Blocker.